Post-Marketing Surveillance of Humira Injection in Korean Patients Under the "New-Drug Re-examination"
Post-Marketing Surveillance of Humira Injection in Korean Patients Under the "New-Drug Re-examination"
Patients who take Humira as prescribed by physicians as per Korean label will be enrolled and observed in normal medical practice setting for not less than 3 months following first dose of Humira. Information on demographics, diagnosis and medical history, results of tuberculosis skin test, results of chest X-ray, Humira treatment information, concomitant medication, physician's global assessment for effectiveness, disease activity assessment for rheumatoid arthritis, disease activity assessment for Crohn's Disease, disease activity assessment for Psoriasis and adverse events will be recorded on case report forms.
Inclusion Criteria:
Adult patients (19 years and above) with one of the following indications:
Patients who give verbal or written authorization to use their personal and health data.
Exclusion Criteria:
- Patients with known hypersensitivity to adalimumab or any of its excipients.
Jeollabuk-do, 651-180, South Korea
Metropolitan City Daejon, 302-718, South Korea
Uljeongbu, 480-824, South Korea